NCT06198465尚未招募2 期
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma: a Prospective, Open-label, Single-center Clinical Study
Xijing Hospital1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年3月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Pathological Complete Response (pCR)
研究概览
简要总结
The goal of this prospective, open-label, single-center clinical study is to learn about the efficacy and safety of aderbelimab combined with chemotherapy in the perioperative treatment of esophageal and esophagogastric junction cancer. The main question it aims to answer are:prediction for pCR after perioperative adebrelimab and chemotherapy in esophageal and esophagogastric junction carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 years, both genders;
- •Histologically or cytological confirmed esophageal and esophagogastric junction cancer (cT3-4, anyN, M0);
- •Without prior treatments including surgery, chemotherapy, radiotherapy, and targeting treatment for esophageal and esophagogastric junction cancer;
- •According to the RECIST v1.1 standard, there must be at least 1 measurable lesion;
- •ECOG PS score 0-1;
- •Adequate organ function, and there are no serious functional abnormalities or immune deficiency diseases such as blood, heart, lung, liver, kidney, bone marrow, etc. Laboratory examinations meet the following requirements:
- •Hemoglobin ≥ 90 g/L; 2) Leukocytes ≥ 3.0x10^9/L; Absolute neutrophil count≥ 1.5x10^9/L; 3) Platelet ≥ 100x10^9/L; 4) Serum creatinine ≤1.5 ULN or creatinine clearance rate≥50 mL/min; 5) Total bilirubin ≤1.5 ULN; 6) ALT ≤2.5 ULN; AST ≤2.5 ULN; 7) Urinary protein <2+; if urine protein≥2+, 24-hour urine protein quantification shows that the protein must be ≤1g;
- •Coagulation function test:
- •INR ≤1.5 ULN;
- •APTT ≤1.5 ULN;
- •PT≤1.5ULN； 8.Previous use of anti-tumor traditional Chinese medicines, Chinese patent medicines, and immunomodulators (such as thymosin, interleukins, etc.) must be ≥ 2 weeks from the start of study medication;
- •For females of child bearing potential, a negative serum/urine pregnancy test result within 72h before study treatment. For female and male participants of reproductive potential must be willing to use adequate contraception for the course of the study until 3 months after the last dose of any of the drugs in the study; 10.Volunteered to participate in the study, signed the informed consent form;
- •Had good compliance and cooperated with the follow-up.
排除标准
- •Suffering from any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (hormone replacement) can be included after treatment); subjects with childhood asthma that has completely resolved and do not require any intervention in adulthood or vitiligo can be included, but subjects who require medical intervention with bronchodilators are not included;
- •People with innate or acquired immune function defects, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU/ml), hepatitis C positive hepatitis C antibody, and high HCV-RNA (lower detection limit of the analytical method) or combined with hepatitis B and hepatitis C co-infection; patients who have used other drugs for clinical trial research within 4 weeks before the first dose;
- •Have had clinically significant bleeding symptoms or have a clear bleeding tendency within 3 months;
- •Such as gastrointestinal bleeding, esophageal and gastric varices with bleeding risk, bleeding gastric ulcer, or vasculitis; a gastroscopy is required during the screening period. If the gastroscopy results indicate severe gastric ulcer or the researcher determines that there is bleeding, If the risk is high, you will not be eligible; gastrointestinal perforation or gastrointestinal fistula has occurred within 6 months;
- •Suffering from uncontrolled cardiac clinical symptoms or diseases, such as (1) NYHA II or above heart failure (2) unstable angina (3) myocardial infarction within 1 year (4) poorly controlled arrhythmia;
- •The number of neutrophils in peripheral blood <1500/mm3;
- •Severe infection (e.g. requiring intravenous infusion of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first dose, or unexplained fever >38.5°C during the screening period/before the first dose;
- •Those who are known to have a history of allergies to the drug components of this regimen;
- •There may be increased risks of participation in research and study medication, or other severe, acute and chronic diseases;
- •Other conditions deemed inappropriate for inclusion by the researcher.
研究组 & 干预措施
adebrelimab combined with chemotherapy
Experimental
干预措施: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil (Drug)
结局指标
主要结局
Pathological Complete Response (pCR)
时间窗: At time of surgery
defined as the absence of any viable tumor at the time of surgical resection, as assessed by central and local pathology laboratory
次要结局
- Number of participants with treatment-related adverse events(6 months)
- Overall Survival (OS)(up to 2 year)
- R0 resection rate(At time of surgery)
- Disease-Free Survival (DFS)(up to 2 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)Adebrelimab (SHR-1316)XELOXGC/GEJCNCT06506292Tianjin Medical University Cancer Institute and Hospital25
招募中
2 期
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal CancerMetastatic Colorectal CancerNCT06231017The First Affiliated Hospital of Zhengzhou University36
尚未招募
2 期
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical TrialEsophageal Squamous Cell CarcinomaNCT06178211Shanghai Chest Hospital36
招募中
2 期
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder CarcinomaNeuroendocrine Carcinoma of the BladderBladder CancerNCT06091124RenJi Hospital22
尚未招募
2 期
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene MutationsNon Small Cell Lung CancerNCT06299371Liaoning Tumor Hospital & Institute36